Savior Lifetec - Asset Resilience Ratio

Latest as of December 2025: 18.86%

Savior Lifetec (4167) has an Asset Resilience Ratio of 18.86% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Savior Lifetec's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets

NT$789.00 Million
≈ $24.86 Million USD Cash + Short-term Investments

Total Assets

NT$4.18 Billion
≈ $131.82 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Savior Lifetec's Asset Resilience Ratio has changed over time. See Savior Lifetec balance sheet quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Savior Lifetec's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Savior Lifetec market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents NT$0.00 0%
Short-term Investments NT$789.00 Million 18.86%
Total Liquid Assets NT$789.00 Million 18.86%

Asset Resilience Insights

  • Good Liquidity Position: Savior Lifetec maintains a healthy 18.86% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Savior Lifetec Industry Peers by Asset Resilience Ratio

Compare Savior Lifetec's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Biotechnology -55.36%
Krystal Biotech Inc
NASDAQ:KRYS
Biotechnology 23.06%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Savior Lifetec (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Savior Lifetec.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 18.86% NT$789.00 Million
≈ $24.86 Million
NT$4.18 Billion
≈ $131.82 Million
+1.47pp
2024-12-31 17.39% NT$761.06 Million
≈ $23.98 Million
NT$4.38 Billion
≈ $137.87 Million
+10.74pp
2023-12-31 6.65% NT$254.27 Million
≈ $8.01 Million
NT$3.82 Billion
≈ $120.44 Million
-6.14pp
2022-12-31 12.79% NT$563.76 Million
≈ $17.76 Million
NT$4.41 Billion
≈ $138.90 Million
+12.44pp
2021-12-31 0.35% NT$15.71 Million
≈ $495.01K
NT$4.54 Billion
≈ $142.99 Million
-2.13pp
2020-12-31 2.47% NT$119.65 Million
≈ $3.77 Million
NT$4.84 Billion
≈ $152.38 Million
+1.88pp
2019-12-31 0.60% NT$24.13 Million
≈ $760.13K
NT$4.03 Billion
≈ $127.07 Million
-1.60pp
2018-12-31 2.19% NT$77.42 Million
≈ $2.44 Million
NT$3.53 Billion
≈ $111.20 Million
+2.18pp
2017-12-31 0.01% NT$420.00K
≈ $13.23K
NT$3.95 Billion
≈ $124.37 Million
--
pp = percentage points

About Savior Lifetec

TWO:4167 Taiwan Biotechnology
Market Cap
$194.15 Million
NT$6.16 Billion TWD
Market Cap Rank
#16753 Global
#835 in Taiwan
Share Price
NT$19.85
Change (1 day)
+0.00%
52-Week Range
NT$17.00 - NT$21.85
All Time High
NT$40.63
About

Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more